Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May;63(5):720-6.
doi: 10.1136/gutjnl-2013-304883. Epub 2013 Jul 5.

Impact of regurgitation on health-related quality of life in gastro-oesophageal reflux disease before and after short-term potent acid suppression therapy

Peter J Kahrilas  1 , Andreas Jonsson, Hans Denison, Börje Wernersson, Nesta Hughes, Colin W Howden
Affiliations

Impact of regurgitation on health-related quality of life in gastro-oesophageal reflux disease before and after short-term potent acid suppression therapy

Peter J Kahrilas et al. Gut. 2014 May.

Abstract

Objective: Limited data exist on the impact of regurgitation on health-related quality of life (HRQOL) in gastro-oesophageal reflux disease (GORD). We assessed the relationship between regurgitation frequency and HRQOL before and after acid suppression therapy in GORD.

Method: We used data from two randomised trials of AZD0865 25-75 mg/day versus esomeprazole 20 or 40 mg/day in non-erosive reflux disease (NERD) (n=1415) or reflux oesophagitis (RO) (n=1460). The Reflux Disease Questionnaire was used to select patients with frequent and intense heartburn for inclusion and to assess treatment response. The Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire was used to assess HRQOL.

Results: At baseline, 93% of patients in both the NERD and RO groups experienced regurgitation. Mean QOLRAD scores were similar for NERD and RO at baseline and at week 4 and disclosed decremental HRQOL with increasing frequency of regurgitation; a clinically relevant difference of >0.5 in mean QOLRAD scores was seen with regurgitation ≥4 days/week versus <4 days/week. The prevalence of frequent, persistent regurgitation (≥4 days/week) at week 4 among heartburn responders (≤1 day/week of mild heartburn) was 28% in NERD and 23% in RO. QOLRAD scores were higher among heartburn responders. There was a similar pattern of impact related to regurgitation frequency in heartburn responders compared with the group as a whole.

Conclusions: Frequent regurgitation was associated with a clinically relevant, incremental decline in HRQOL beyond that associated with heartburn before and after potent acid suppression in both NERD and RO.

Clinical trial numbers: NCT00206284 and NCT00206245.

Keywords: Anti-Reflux Therapy; Gastroesophageal Reflux Disease; Oesophageal Reflux; Oesophagitis; Quality of Life.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Peter Kahrilas has acted as a consultant for AstraZeneca, Eisai, EndoGastric Solutions, Ironwood, Novartis, and XenoPort. Andreas Jonsson, Hans Denison and Börje Wernersson are employees of AstraZeneca R&D, Mölndal, Sweden. Nesta Hughes is an employee of Oxford PharmaGenesis™ Ltd, Oxford, UK, which has received funding from AstraZeneca R&D, Mölndal, Sweden. Colin Howden has acted as a consultant for Boehringer Ingelheim, Novartis Consumer Health, Novartis Oncology, Otsuka, Takeda, Perrigo and XenoPort, and as a speaker for Novartis, Otsuka, Ironwood, Forest Laboratories, Takeda and GlaxoSmithKline.

Figures

Figure 1
Figure 1
The proportion of patients with regurgitation at baseline. NERD, non-erosive reflux disease; regurgitation–movement, unpleasant movement of material upwards from the stomach; regurgitation–taste, an acid taste in the mouth; regurgitation, the presence of an acid taste in the mouth and/or unpleasant movement of material upwards from the stomach; RO, reflux oesophagitis.
Figure 2
Figure 2
Mean QOLRAD scores (error bars represent 95% confidence intervals) according to the presence and frequency of regurgitation at baseline for patients with (A) NERD (B) RO. *The number of patients with daily regurgitation in the physical/social functioning dimension was 387, rather than 388 as in the other dimensions (missing data). NERD, non-erosive reflux disease; QOLRAD, The Quality of Life in Reflux and Dyspepsia; regurgitation, the presence of an acid taste in the mouth and/or unpleasant movement of material upwards from the stomach; RO, reflux oesophagitis.
Figure 3
Figure 3
Mean QOLRAD scores (error bars represent 95% confidence intervals) according to the presence and frequency of persistent regurgitation at week 4 for patients with (A) NERD and (B) RO. NERD, non-erosive reflux disease; QOLRAD, The Quality of Life in Reflux and Dyspepsia; regurgitation, the presence of an acid taste in the mouth and/or unpleasant movement of material upwards from the stomach; RO, reflux oesophagitis.
See this image and copyright information in PMC

References

    1. van Pinxteren B, Sigterman KE, Bonis P, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2010:CD002095. - PubMed
    1. El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther. 2010;32:720–37. - PubMed
    1. Donnellan C, Sharma N, Preston C, et al. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev. 2005;2:CD003245. - PubMed
    1. Kahrilas PJ, Howden CW, Hughes N. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease. Am J Gastroenterol. 2011;106:1419–25. - PubMed
    1. Kahrilas PJ, Jonsson A, Denison H, et al. Regurgitation is less responsive to acid suppression than heartburn in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2012;10:612–9. - PubMed

Publication types

MeSH terms

Associated data